Editas expands cooperation to jointly develop eye disease gene therapy

Editas expands cooperation to jointly develop eye disease gene therapy

January 30, 2018 Source: WuXi PharmaTech

Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];

Adverum Biotechnologies (hereinafter referred to as Adverum) recently announced the expansion of its cooperation agreement with Editas Medicine (hereinafter referred to as Editas). The two companies announced a partnership in August 2016 to collaborate on the development of genome-editing drugs to treat five hereditary retinal diseases. Under the terms of the expansion agreement, Adverum and Editas extended the study period to the third quarter of 2018; from now until August 2020, Editas retained a series of viable powers.

Adverum is a clinically-based gene therapy company focused on unmet medical needs for severely rare and eye diseases. Adverum has a strong development pipeline that includes candidates for the treatment of rare diseases such as alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) and wet age-related macular degeneration (wAMD). Using a technology platform based on a new generation of adeno-associated virus (AAV) vectors, Adverum provides long-lasting efficacy by inducing sustained expression of therapeutically effective proteins.

Founded in 2013, Editas Medicine is a world leader in genome editing, protein engineering, molecular and structural biology. This innovative genome editing company specializes in genome editing technologies such as CRISPR/Cas9 and TALENs. The company's mission is to transform genome editing techniques into new drugs and therapies, using precise molecular modification techniques to edit and correct genomes, and to treat the underlying causes of many diseases at the genetic level.

The collaboration between Adverum and Editas aims to develop methods for the treatment of hereditary retinal diseases with genomic editing drugs. In addition, Adverum has a partnership agreement with Regeneron Pharmaceuticals to jointly develop and commercialize eye disease gene therapy products.

â–² Dr. Amber Salzman, President and CEO of Adverum (Source: Adverum Official Website)

“Our collaboration with Editas focuses on using our next-generation AAV carrier to deliver Editas' CRISPR-based genome editing technology to develop new treatments,” said Dr. Amber Salzman, President and CEO of Adverum. “We work together. The expansion of the relationship proves the importance of our next generation of carriers in this work."

â–²Ms. Katrine Bosley, CEO of Editas (Source: Editas Official Website)

Editas CEO Katrine Bosley said: "This collaboration combines our best-in-class genome editing platform with Adverum's industry-leading carrier technology to develop new drugs for patients with retinal diseases. Adverum has unique technology and importance Ophthalmology experience. Expanding our partnership reflects our continued strategy of highly selective investment in the genome editing platform."

Reference materials:

[1] Adverum Biotechnologies and Editas Medicine Extend Research Collaboration

Neck Massage

Best Neck Massager,Shiatsu Neck Massager,Neck Relax Massager,Best Massage For Neck Pain

Shenzhen Jie Zhong Lian Investment Co., Ltd. , https://www.szmeizons.com